MA09.03 Plasma Proteomics-based Models for Predicting Immunotherapy- and Chemotherapy-Related Toxicity in NSCLC PatientsJarushka Naidoo, Yehonatan Elon, David R. Gandara et al.|Journal of Thoracic Oncology|2024Cited by 0
P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving ImmunotherapyDavid R. Gandara, M.A. Schneider, Igor Puzanov et al.|Journal of Thoracic Oncology|2024Cited by 0